Volatile Organic Compound Based Probe for Induced Volatolomics of Cancers

Abstract

The development of efficient protocols for cancer diagnosis remains highly challenging. An emerging approach relies on the detection in exhaled breath of volatile organic compounds (VOC) produced by tumours.I nt his context, described here is anovel strategy in whichaVOC-based probe is converted selectively in malignant tissues,b yatumourassociated enzyme,for releasing the corresponding VOC. The latter is then detected in the exhaled breath as atumour marker for cancer diagnosis.T his approach allows the detection of several different tumours in mice,t he monitoring of tumour growth and tumour response to chemotherapy. Thus,t he concept of "induced volatolomics" provides an ew way to explore biological processes using VOC-based probes that could be adapted to many biomedical applications.

Synthetic Artificial Apoptosis‐Inducing Receptor for On‐Demand Deactivation of Engineered Cells

“…Indeed, activation of the corresponding substrates, glucuronides, in the human body is only associated with diseased tissues such as cancer, and not with normal healthy tissues. [25][26][27] Glucuronides are also highly advantageous for receptor design as being highly polar: [28][29] the use of glucuronic acid as a removable masking group is poised to ensure exofacial localization and accessibility of the trigger to enzymatic activation. As an effector molecule, we used a highly potent intracellular toxin, monomethyl auristatin E (MMAE), which has excellent lipophilicity and cell permeability properties (calculated log P = 3,5).…”

29th Annual GP2A Medicinal Chemistry Conference

“…Within this framework, we developed various molecular devices programmed for the selective delivery of anticancer drugs (Figure 2). These functional systems were designed to allow: (1) the transport in the body of potent anticancer agents in an innocuous manner toward safe tissues, (2) the efficient recognition of malignant specificities located either at the surface of cancer cells or in the tumor microenvironment, and (3) the controlled release of the parent drug exclusively at the tumor site. Such compounds include programming components such as self-immolative linkers, chemical amplifiers, self-opening macrocycles, enzyme-responsive biorthogonal triggers, and so on, which pilot the process of drug release in a stringently controlled fashion [1][2][3][4][5][6][7][8][9].…”

“…Catalin Zaharia 1 , Ionut-Cristian Radu 1 , Bianca Galateanu 2 , Eugenia Tanasa 1 , Madalina Necolau 1 1…”

“…Catalin Zaharia 1 , Ionut-Cristian Radu 1 , Bianca Galateanu 2 , Eugenia Tanasa 1 , Madalina Necolau 1 1 Advanced Polymer Materials Group, Politehnica University of Bucharest, 1-7 Gh. Polizu Street, 011061 Bucharest, Romania.…”

“…Marion Flipo 1 , Baptiste Villemagne 1 , Priscille Brodin 2 , Benoit Deprez 1 , Alain Baulard 2 , Nicolas Willand 1…”